AbbVie Inc. (ABBV)

NYQ – Real Time Price. Currency in USD

207.86

+5.08 (2.51%)

At close: May 12, 2026, 4:01 PM EDT

206.30

-1.66 (-0.80%)

Pre-market: May 13, 2026, 9:09 AM EDT

12.05.2026

AbbVie's Growth Engine Is Firing On All Cylinders

AbbVie is a compelling 'Buy' as it has strong momentum in existing drugs and has a robust pipeline. Robust Q1 2026 results: net revenue up 12.4% YoY, driven by Immunology (Skyrizi +29%, Rinvoq +20%) and Neuroscience (+24%). Management raised 2026 EPS guidance to $14.18, signaling 42% YoY growth and confidence in ABBV's diversified growth drivers and pipeline.

12.05.2026

AbbVie Deserves A Higher Multiple

AbbVie remains a buy as fundamentals strengthen and valuation sits near multiyear lows after recent stock underperformance. Q1 net revenues grew 12.4% YoY, indicating robust overall business activity despite some Immunology portfolio shakiness. Raised full-year 2026 EPS guidance signals management confidence, with underlying EPS growth projected at 14% annually after adjusting for IPR&D and milestone impacts.

11.05.2026

A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?

AbbVie's Skyrizi is one of its most important growth drivers. This drug could face competition from a newer medicine under development that appears more effective.

11.05.2026

AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing

AbbVie (ABBV) delivered strong Q1 2026 results, with $15B revenue (+12.4% YoY) and Skyrizi sales up 30.9%, prompting raised EPS guidance. Despite analyst concerns over new oral competitors like Icotyde, Skyrizi maintains a clear efficacy advantage and expanding indications, supporting robust growth. ABBV is trading at 14.2x 2026 EPS with a 0.84x PEG, offering compelling value amid 17% projected earnings growth and a $250/share price target.

09.05.2026

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

AbbVie NYSE: ABBV told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development.

06.05.2026

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

06.05.2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

NORTH CHICAGO, Ill., May 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026.

Videos

01.05.2026

Negative

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

13.01.2026

Positive

AbbVie reaches 3-year deal with White House to lower drug prices

17.12.2025

Neutral

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

14.11.2025

Positive

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
ABBV	Citigroup	Neutral	undefined >> $205	May 14th 2025
ABBV	Cantor Fitzgerald	Overweight	undefined >> $210	April 22nd 2025
ABBV	Daiwa Securities	Neutral	undefined >> $180	December 5th 2024
ABBV	Leerink Partners	Outperform	undefined >> $206	November 22nd 2024
ABBV	Wolfe Research	Outperform	undefined >> $205	November 15th 2024
ABBV	Argus	Buy	undefined >> undefined	November 4th 2024
ABBV	Bernstein	Market Perform	undefined >> $203	October 17th 2024
ABBV	HSBC Securities	Buy	undefined >> $185	June 5th 2024

Press releases

05.05.2026

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, and durability NORTH CHICAGO, Ill., May 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago.

30.04.2026

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Through its loyalty rewards program Allē, Allergan Aesthetics will donate to The Skin Cancer Foundation $10 for every new member who joins from a referral in May, up to $100,000. IRVINE, Calif.

29.04.2026

AbbVie Reports First-Quarter 2026 Financial Results

Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $15.002 Billion, an Increase of 12.4 Percent on a Reported Basis or 10.3 Percent on an Operational Basis First-Quarter Global Net Revenues from the Immunology Portfolio Were $7.290 Billion, an Increase of 16.4 Percent on a Reported Basis, or 14.3 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.483 Billion; Global Rinvoq Net Revenues Were $2.119 Billion; Global Humira Net Revenues Were $688 Million First-Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.875 Billion, an Increase of 26.0 Percent on a Reported Basis, or 24.3 Percent on an Operational Basis; Global Vraylar Net Revenues Were $905 Million; Global Botox Therapeutic Net Revenues Were $1.009 Billion; Combined Global Ubrelvy and Qulipta Net Revenues Were $635 Million; Global Vyalev Net Revenues Were $201 Million First-Quarter Global Net Revenues from the Oncology Portfolio Were $1.631 Billion, a Decrease of 0.2 Percent on a Reported Basis, or 3.0 Percent on an Operational Basis; Global Venclexta Net Revenues Were $770 Million; Global Imbruvica Net Revenues Were $556 Million; Global Elahere Net Revenues Were $198 Million First-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.186 Billion, an Increase of 7.6 Percent on a Reported Basis, or 5.1 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $668 Million; Global Juvederm Net Revenues Were $232 Million Raises 2026 Adjusted Diluted EPS Guidance Range from $13.96 - $14.16 to $14.08 - $14.28, which Includes an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the First Quarter 2026 NORTH CHICAGO, Ill., April 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2026.

28.04.2026

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Submission is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of severity of alopecia tool (SALT) score ≤ 20 at week 24, with additional efficacy results observed at week 52 1-3 Upadacitinib is also the first JAK inhibitor to meet the ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 24 1-3 NORTH CHICAGO, Ill., April 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA), based on results from the Phase 3 UP-AA clinical program.1-3 "Alopecia areata is a chronic immune-mediated disease in which the physical and psychological burden patients can experience goes far beyond hair loss, impacting their day-to-day lives," said Kori Wallace, M.D.

AbbVie Inc. (ABBV)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AbbVie Inc. (ABBV)